West Health mosaic Logo
Website
Video

Regardless of Political Party, Americans Overwhelmingly Support Medicare Drug Price Negotiations

September 30, 2024

A new West Health-Gallup poll shows 83% of the U.S. population favors Medicare being allowed to negotiate with drug companies to lower prescription drug prices for its recipients.

Pills in hand
Time to read icon
1 Minute Read
Share

As the pharmaceutical industry ramps up efforts to fight the U.S. government’s historic Medicare Drug Price Negotiation Program, a new West Health-Gallup public opinion survey shows overwhelming bipartisan support for the program, which is forecast to save $100 billion in its first decade.
“No matter who they vote for, Americans are suffering from the high costs of prescription drugs,” says Tim Lash, president of West Health, a family of nonprofit organizations focused on reducing healthcare costs and improving quality of care. “The public’s overwhelming support for this policy, even as we head into a presidential election, makes one thing exceedingly clear: people know unfair, anticompetitive behavior when they see it and they want it to stop.”

Related Reading
Research
Trending
As the pharmaceutical industry ramps up efforts to fight the U.S. government’s historic Medicare Drug Price Negotiation Program, a new West Health-Gallup public opinion survey shows overwhelming bipartisan support for the program, which is forecast to save $100 billion in its first decade.Abstract“No matter who they vote for, Americans are suffering from the high costs of prescription drugs,” says...
Video
Trending
Story
Article
TestTestTestTestAs the pharmaceutical industry1 ramps up efforts to fight the U.S. government’s historic Medicare Drug Price Negotiation Program, a new West Health-Gallup public opinion survey shows overwhelming bipartisan support for the program, which is forecast to save $100 billion in its first decade.As the pharmaceutical industry1 ramps up efforts to fight the U.S. government’s historic Medi...
Website
Video
Toolkit
Key takeawaysDespite the availability of a generic version, most HIV preexposure prophylaxis (PrEP) prescriptions for commercially insured patients from 2019 to 2021 were for branded formulations, particularly Descovy (TAF/FTC).Providers substantially overprescribe Descovy relative to its clinical value, with Descovy accounting for nearly half of 2021 commercial PrEP utilization and 60% of spendin...